Marijuana Rescheduling 2026: What It Means for You

A senior couple's hands holding a CBD oil tincture bottle at their kitchen table, illustrating Trump's September 2026 marijuana rescheduling order

Seniors are among the heaviest users of CBD products for pain — and President Trump asked Congress this week to make those products easier for them to get. Image: TechPulse USA

Published September 20, 2026 · By Daniel Rao

On Thursday afternoon, in an Oval Office ceremony flanked by his health secretary and the head of Medicare, President Donald Trump signed the executive order cannabis advocates have chased for a decade — while insisting, on the record, that it is not legalization.

The order tells Attorney General Pam Bondi to finish moving marijuana out of Schedule I — the federal government's most restrictive category, where cannabis has sat beside heroin and LSD since the 1970s — and into Schedule III. The rescheduling process began under President Biden, stalled at the Drug Enforcement Administration, and drew tens of thousands of public comments.

"We have people begging for me to do this," Trump said at the signing. "People that are in great pain." Here is the plain-English version of what actually changes — for patients, seniors, researchers and the cannabis business — and what the order deliberately leaves untouched.

The Thursday signature: what Trump actually ordered

The order does not reclassify marijuana by itself. Only a completed Justice Department rulemaking — an administrative hearing, a published final rule, then a waiting period — can change the schedule. What Trump did was demand the stalled process move "as quickly as legally possible."

The guest list was the message: Health Secretary Robert F. Kennedy Jr. and Medicare chief Dr. Mehmet Oz stood beside the president. Bloomberg reported Trump had discussed the move with both men — and had also spoken with cannabis industry leaders, including Kim Rivers, chief executive of Trulieve Cannabis Corp., one of the largest US marijuana companies. No firm timeline was announced; analysts following the process estimate three to six months if the administration pushes hard.

Schedule I vs. Schedule III: the 60-second explainer

Think of the federal drug schedules as a ladder. Schedule I is the top rung: the government claims no accepted medical use and high abuse potential. Schedule III sits far lower: accepted medical use, moderate-to-low dependence risk. Ketamine and some anabolic steroids are Schedule III drugs.

For the first time, the federal government formally acknowledges that cannabis has legitimate medical uses — a direct contradiction of the 50-year-old Schedule I label.

What changes for patients — starting with pain

The clearest win is for medical research. Under Schedule I, scientists were mostly limited to cannabis grown at federally approved facilities — a tiny supply that strangled serious trials. Rescheduling lets researchers study state-legal products, the same things millions of patients actually use. That opens the door to FDA-reviewed cannabis medicines and a real evidence base.

The patient population is huge. Federal data puts chronic pain at nearly 1 in 4 US adults, with the share climbing with age, and industry figures put pain management as the reason for about 6 in 10 medical marijuana users. A 2023 Health and Human Services review counted more than 30,000 licensed practitioners across 43 jurisdictions recommending medical cannabis to over 6 million registered patients; forty states plus Washington, D.C. now run medical marijuana programs.

One honest caveat: rescheduling does not automatically make medical marijuana cheaper, covered by insurance, or legal in your state. State law still governs who can buy what and where. But it makes the conversation with your doctor easier — and gives science a fair chance to answer which uses genuinely work.

The seniors' footnote: Trump's CBD request to Congress

Tucked into the announcement was a line aimed squarely at older Americans. Trump said he has asked Congress to reconsider the classification of hemp-derived CBD, "to ensure seniors can access CBD products that they have found beneficial for pain and other reasons."

That matters because seniors are among America's most pain-burdened residents — and CBD, the non-intoxicating cannabis compound sold in tinctures and gummies, sits in a legal gray zone that varies state by state.

What seniors should do now: talk to your doctor before starting or changing any cannabis or CBD product, buy only from licensed sellers with third-party lab testing, and check your own state's rules. Medicare does not cover medical marijuana or CBD, and this order does not change that by itself.

What changes for the cannabis business: the 280E tax break

Here is the sleeper provision that could reshape the industry. IRS tax code 280E bars businesses dealing in Schedule I or II substances from deducting ordinary expenses — rent, payroll, advertising — taxing them as if those costs did not exist. Moving to Schedule III lifts 280E: lower effective tax rates, healthier balance sheets, cheaper capital.

Analysts say the change could also draw larger pharmaceutical companies into the sector and clear the path for more FDA-reviewed cannabis medicines. For consumers, that is not abstract: well-capitalized, properly taxed legal businesses are the ones that can afford consistent testing, accurate labeling and stable prices — the difference between a safe product and a gamble.

Alabama just blinked: the state dominoes are already falling

The first state-level ripple landed Friday, one day after the signing: an Alabama legislative committee unanimously withdrew its objection to aligning state law with the federal move, after health officials concluded it would not disrupt Alabama's medical cannabis program.

That program, created in 2021, is tightly limited — three dispensaries open now, seven more expected within months, up to nearly 40 at full capacity, with no smoking, vaping, home cultivation or recreational sales. A state health official noted the program was "already live, even though it's still Schedule I in Alabama," because the statute was written to protect authorized patients.

Federal Schedule III status gives cautious legislatures political cover to modernize their cannabis policies without leading a legalization charge.

What it does NOT do: Trump's own red lines

Trump was emphatic at the signing: "I want to emphasize that the order I am about to sign does not legalize marijuana in any way, shape or form and in no way sanctions its use as a recreational drug." Read that twice:

Recreational marijuana remains illegal under federal law, with criminal penalties unchanged.
Your state still decides. States with no medical program need not create one; strict states keep their rules.
Carrying cannabis across state lines is still a federal crime, and federal workplaces should assume nothing about drug testing has changed.
It is not instant. Until the Justice Department finishes the rulemaking and the final rule takes effect, the old classification stands.

Why it matters — our honest verdict

This is the biggest shift in federal drug policy in more than 50 years, and its real prize is research: for decades, scientists were barred from studying the products patients actually use. That era is ending.

The honest verdict: this is a door-opener, not a finish line. The rulemaking must still survive its hearing and comment gauntlet, Congress must still decide on CBD, and states still write the rules that touch your daily life. But for the millions of Americans managing chronic pain — especially seniors buying CBD in a legal fog — Thursday's signature moved Washington from denial to recognition. That is what the whole fight was about.

Watching household costs? See our grocery inflation 2026 guide and our fall vaccines 2026 guide for seniors.

Frequently asked questions

Is marijuana now legal at the federal level?
No. The order starts the process of moving cannabis from Schedule I to Schedule III — recognizing medical use and easing restrictions — but it does not legalize recreational marijuana, and criminal penalties are unchanged.

When does rescheduling take effect?
Not yet. The Justice Department must finish its hearing, publish a final rule and allow the usual 30-to-60-day waiting period. Analysts estimate three to six months; the order set no firm deadline.

Will Medicare or insurance cover medical marijuana now?
No — not automatically. Rescheduling opens the door to future coverage discussions and makes FDA-reviewed cannabis medicines more likely, but no coverage change was announced.

I'm a senior using CBD for pain. What should I do?
Nothing in this order restricts CBD. Trump asked Congress to clarify hemp-derived CBD rules for seniors, but until Congress acts, keep talking to your doctor, buy from licensed sellers with lab testing, and follow your state's rules.

Does this change drug testing at work?
Assume nothing has changed. Federal workplace rules and most employer policies are separate from drug scheduling — check with your employer.

Search This Blog

TechPulse USA